Predicts risk of 50% decline in eGFR or end-stage kidney disease in patients with IgA nephropathy. This validated prediction tool was developed using an international multi-ethnic cohort of 2,781 patients with biopsy-proven idiopathic IgA nephropathy. The tool uses clinical, laboratory, and histological parameters available at biopsy to provide risk estimates for kidney function decline. Two versions are available: one including race/ethnicity and one without race. The tool is endorsed by the 2021 KDIGO guidelines as the preferred method to predict kidney outcomes in IgA nephropathy patients. It facilitates clinical decision-making, patient counseling, and clinical trial enrollment by stratifying patients based on their risk of progressive kidney disease.
Awaiting Clinical Input
Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.
The International IgA Nephropathy Prediction Tool is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within nephrology.
Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.
5-year risk <10%
5-year risk 10-25%
5-year risk 25-50%
5-year risk 50-75%
5-year risk >75%
Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.
Open in Web AppClinical Decision Support (CDS) Notice & Legal Disclaimer
This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.